$549 Million is the total value of Aisling Capital LLC's 17 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 5.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LOXO | Buy | LOXO ONCOLOGY INC | $176,270,000 | +36.2% | 4,188,920 | +4.0% | 32.09% | +6.7% |
| ZLTQ | ZELTIQ AESTHETICS INC | $89,516,000 | +27.8% | 1,609,727 | 0.0% | 16.30% | +0.1% | |
| AIMT | AIMMUNE THERAPEUTICS INC. | $64,973,000 | +6.3% | 2,990,000 | 0.0% | 11.83% | -16.8% | |
| VRAY | VIEWRAY INC. | $63,662,000 | +171.9% | 7,480,887 | 0.0% | 11.59% | +112.9% | |
| VSAR | Sell | VERSARTIS INC | $43,222,000 | +14.9% | 2,024,465 | -19.8% | 7.87% | -10.0% |
| ESPR | Sell | ESPERION THERAPEUTICS INC. | $29,559,000 | +44.2% | 837,125 | -48.9% | 5.38% | +12.9% |
| ADMA | ADMA BIOLOGICS INC | $17,608,000 | -4.7% | 3,608,171 | 0.0% | 3.21% | -25.4% | |
| TTOO | T2 BIOSYSTEMS INC | $14,891,000 | 0.0% | 2,830,992 | 0.0% | 2.71% | -21.7% | |
| TRXC | TRANSENTERIX INC. | $10,086,000 | -6.9% | 8,335,819 | 0.0% | 1.84% | -27.1% | |
| PRTK | PARATEK PHARMACEUTICALS INC | $9,292,000 | +25.0% | 482,680 | 0.0% | 1.69% | -2.1% | |
| SYRS | SYROS PHARMACEUTICALS, INC. | $8,101,000 | +31.0% | 508,565 | 0.0% | 1.48% | +2.6% | |
| CDTX | CIDARA THERAPEUTICS INC. | $7,965,000 | -25.0% | 1,021,148 | 0.0% | 1.45% | -41.3% | |
| AGRX | AGILE THERAPEUTICS INC | $5,776,000 | -43.9% | 1,804,933 | 0.0% | 1.05% | -56.0% | |
| XENT | INTERSECT ENT INC | $3,859,000 | +41.7% | 225,000 | 0.0% | 0.70% | +11.1% | |
| CMRX | CHIMERIX INC. | $3,017,000 | +38.6% | 472,943 | 0.0% | 0.55% | +8.5% | |
| PTXTQ | PERNIX THERAPEUTICS HLDGS IN | $777,000 | +90.9% | 210,000 | 0.0% | 0.14% | +48.4% | |
| PERNIX THERAPEUTICS HLDGS INCdebt | $688,000 | +10.1% | 2,500,000 | 0.0% | 0.12% | -13.8% | ||
| CEMP | Exit | CEMPRA INC | $0 | – | -1,193,060 | -100.0% | -0.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TRANSENTERIX INC. | 22 | Q3 2019 | 12.1% |
| CHIMERIX INC. | 21 | Q4 2018 | 19.4% |
| ADMA BIOLOGICS INC. | 20 | Q3 2019 | 35.5% |
| LOXO ONCOLOGY INC. | 18 | Q4 2018 | 80.9% |
| AIMMUNE THERAPEUTICS INC. | 17 | Q3 2019 | 68.7% |
| CIDARA THERAPEUTICS INC. | 17 | Q3 2019 | 4.1% |
| AGILE THERAPEUTICS INC. | 16 | Q1 2018 | 5.5% |
| ZELTIQ AESTHETICS INC | 14 | Q3 2017 | 16.3% |
| ESPERION THERAPEUTICS INC NE | 14 | Q3 2017 | 24.9% |
| VERSARTIS INC | 13 | Q2 2017 | 16.2% |
View Aisling Capital LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-13 |
| 13F-HR | 2019-08-08 |
| 13F-HR | 2019-05-07 |
| 13F-HR | 2019-02-11 |
| 13F-HR | 2018-11-05 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| 13F-HR | 2018-02-07 |
| 13F-HR | 2017-11-09 |
| 13F-HR | 2017-08-14 |
View Aisling Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.